Clinical Trial Detail

NCT ID NCT04095689
Title TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer
Recruitment Not yet recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors The Methodist Hospital System
Indications

triple-receptor negative breast cancer

Therapies

Cyclophosphamide + Docetaxel + Doxorubicin + IL-12 gene + L-NMMA + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.